RT @Diabetes_Ther: It is UK #diabetesweek this week, and we will be sharing our top 5 downloaded papers with you all. Starting us off: SGL…
RT @Diabetes_Ther: It is UK #diabetesweek this week, and we will be sharing our top 5 downloaded papers with you all. Starting us off: SGL…
RT @Diabetes_Ther: It is UK #diabetesweek this week, and we will be sharing our top 5 downloaded papers with you all. Starting us off: SGL…
RT @Diabetes_Ther: It is UK #diabetesweek this week, and we will be sharing our top 5 downloaded papers with you all. Starting us off: SGL…
It is UK #diabetesweek this week, and we will be sharing our top 5 downloaded papers with you all. Starting us off: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice You can read the full consensus paper online: ht
RT @drkevinfernando: @DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf You might also find this Steering Committee paper…
@DrRaniKhatib @drpatrickholmes @AmarPut @bananabeba @DiabetesUKProf You might also find this Steering Committee paper helpful too https://t.co/PpEStYc4O2 Again open access. We've just had a 3rd paper accepted which I will disseminate as soon as available
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
@kevbizarre @mark_borthwick @CardioPharmUK Unfortunately depending on your criteria these two articles are industry funded (to get us in the room together) but had no input into output /content of these two articles - I wouldnt be involved otherwise http
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @Diabetes_Ther: Improving #Diabetes Steering Committee's newest paper online to read now: #SGLT2 Inhibitors: #Cardiovascular Benefits Be…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @Diabetes_Ther: Improving #Diabetes Steering Committee's newest paper online to read now: #SGLT2 Inhibitors: #Cardiovascular Benefits Be…
Improving #Diabetes Steering Committee's newest paper online to read now: #SGLT2 Inhibitors: #Cardiovascular Benefits Beyond #HbA1c—Translating Evidence into Practice https://t.co/NFLgAs3ctO https://t.co/ncXVb4dmMv
Natriuresis and osmotic diuresis as a result of SGLT-2 inhibitors improves blood pressure and cardiovascular risk. Diabetes guidelines needs updating in terms of suggested treatment pathways. Ali et al (2019) https://t.co/Wv2PYLrpR1
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @Diabetes_Ther: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. Full article available #OpenA…
RT @alicia_bentham: Can't help but love these drugs. BP and weight reduction, decreased visceral fat, arterial stiffness and microalbuminur…
RT @Diabetes_Ther: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. Full article available #OpenA…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @Diabetes_Ther: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. Full article available #OpenA…
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice. Full article available #OpenAccess here: https://t.co/QBqJyZuXep #T2DM https://t.co/PQrvFglTS1
RT @PokrajacAna: One for our team to consider @DamianFog @Roxytonin @ABCDiab @sama_wilkinson https://t.co/0P3Pgg6BNr
One for our team to consider @DamianFog @Roxytonin @ABCDiab @sama_wilkinson
Can't help but love these drugs. BP and weight reduction, decreased visceral fat, arterial stiffness and microalbuminuria - SGLT2 inhibitors
@fiwi14
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
RT @drkevinfernando: Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce ou…
Following our popular SGLT2i evidence & implications for clinical practice review paper, I am delighted to announce our 2nd paper on SGLT2i CV benefits beyond HbA1c—translating evidence into practice. Open access paper with free pdf download https://t
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
sharing information helps us as health professionals to work together
Excellent piece on #SGLT2 and #CV benefits by many of our #diabetes heroes Agreed- we #lovethediagrams! ESSENTIAL READING for #GPPharmacists as translates the findings of #CV Outcomes Trials #CVOT affects your clinical decision-making and individualisatio
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
RT @PNewlandJones: Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotF…
Good work ! #T2Diabetes #CVOT
Very nice! @youngdiab @ABCDiab @DSNforumUK @CardRenalForum @BrJCardiol @DrDerekConnolly @GauravGulsin @RCPLondon
Very happy to share our second paper on #CV benefits of #SGLT2 inhibitors. #diabetes #lovethediagrams https://t.co/iotFw2I4MH